DNLI
Denali Therapeutics Inc
1 day chart
About DNLI
Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.
Buy US stocks in Australia starting with DNLI. Open an account and start investing today!
$4.31B
-
0.00%
121.01K
$31.58
$30.47
$30.87
$39.43
$20.76
DNLI FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in DNLI
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.